The 2nd World Congress on Clinical Lipidology

Vienna, Austria
Cardiology, Hypertension, Dyslipidemia, Endocrinology, Family Medicine, Nephrology, Obesity, Cardio Metabolic Syndrome, Diabetes, Internal Medicine
Imaging – Innovative & Routine Methods, Diagnostics, Clinical Trials, Nutrition, Physical Activity Professionals

Schedule of Presentations:

Friday, December 5, 2014
06:00:00 New Presentation Maciej Banach
18:30:00 Opening Lecture : New Targets and Emerging Therapies Philip Barter, Gerhard M. Kostner
19:30:00 Cocktai l Reception
Saturday, December 6, 2014
06:00:00 Industry Sponsored Symposium
08:00:00 Official opening: Karam Kostner , Australia Plenary 1 Ballroom Johan Strauss What Can We Take Away From Lipid Lowering Gui delines Around The World ? (joint session with EAS): Alberico Catapano, Brian Tomlinson
08:30:00 ACC/AHA Blood Cholesterol Guidelines: Re - examining the Evide nce
09:30:00 Severe Hypertriglyceridemia David Colquhoun
09:30:00 Paediatric FH - man agement
09:30:00 Workshop 1 L ipid Management For Primary Care Maciej Banach
09:30:00 Workshop 2 Management Of Paediatric Dyslipidemia Joep Banach Defesche
10:00:00 Low HDL Maciej Banach
10:00:00 When Do We Need To Treat Lipids In Non FH children?
10:30:00 Panel Discussion
10:30:00 Mixed Dyslipidemia Karam Kostner
11:00:00 Tea/ Coffee Break , Exhibition and Poster Viewing
11:30:00 Lipoprotein Remnants: How to measure and how to treat
11:30:00 Plenary 2 Ballroom Johan Strauss Residual Dyslipidemias
12:00:00 LDL Lowering in CV prevention: Is lower better?
12:30:00 Oral Abstracts
12:30:00 Successful Direct Adsorption of Lipoproteins (DALI) Apheresis during Pregn ancy in an Omani Woman Suffering from Homozygous Familial Hypercholesterolemia
12:35:00 Is Primary Percutaneous Stent Impl antation J ustified by Worse Outcome after Coronary Artery Bypass Grafting in Obese Patients?
12:40:00 The Role of Plasma Triglyceride/High - Density Lipoprotein Cholesterol Ratio to Predict Cardiovascular Outcomes in Chronic Kidney Disease
12:45:00 Changes In The Red Blood Cells Phospholipid Membranes Fatty Acids Spectrum In Patients With Ischemic Heart Disease
12:50:00 The Clinical Significance of Lipoprotein Subfractions and Erythrocyte Membrane Cholesterol in Projection of the Severity of Coronary Artery Disease
12:55:00 The Dyslipidemia International Study (DYSIS)II - Lipid Target Achievement Among Very High Risk Patients With Coronary Heart Disease :Rationale and Design
13:00:00 Prevalence of Lipid Abnormalities among Treated Patients with Stable CHD: The Dyslipidemia International Study (DYSIS) II - Belgium Results
13:05:00 Prevalence of Lipid Abnormalities among Treated Patients with Stable CHD: The Dyslipidemia International Study (DYSIS)II Russia - Results
13:10:00 Pattern of Dyslipidemia Among Patient s with Coronary Artery Disease Admitted to Tertiary Hospital in Central Nepal - A Prospective Observational Study
13:15:00 Homozygous Familial Hypercholesterolemia Presents With A Wide Spectrum of LDL - C Levels In A Genetically Confirmed Cohort Of Patients
13:20:00 Lactobacillus Plantarum TN8 Exhibit s Protective Effect s On Lipid, Hepatic And Ren al Profiles In Obese Rat
13:25:00 IDOL N342S Gene Variant Is Not Associated With Plasma Lipid Profile Andpre - Clinical Carotid Atherosclerosis In Italian Free Living Population
13:30:00 Regional Differ ences Of Serum Lipid Profiles Among Mongolian Older People
13:35:00 Low density lipoprotein triglycerides and mortality: The Ludwigshafen Risk and Cardiovascular Health Study
13:40:00 Sta tin Treated Patients At Very High Cardiovascular Risk In Europe: Are The Majority Close to LDL - C
13:45:00 The Importance of Considering Low - Density Lipoprotein Cholesterol Respo nse, Number Needed to Treat as w ell as Cardiovasc ular Risk in Deciding Who Can Benefit From Statin Therapy
13:50:00 ERK1/2 Mediates Lipopolysaccharide - Upregulated FGF - 2, uPA, MMP - 2, MMP - 9 and Cellular Migration In Primary Cardiac Fibroblasts
13:55:00 The Factors Associated With Failure To Attain Low - Density Lipoprotein Cholesterol Goal At 1years After PCI In ACS Patients
14:00:00 Workshop 4 HDL,TG, Lp(a)
14:00:00 Definition of Statin Intolerance
14:00:00 Lp(a): When to measure and treat
14:00:00 Workshop 3 Statin Resistance/Intolerance Ian Hamilton Craig
14:30:00 Afamin as a novel marker for metabolic syndrome and related disease
14:30:00 Statin Intolerance: Therapeutic Options
15:00:00 The r ole of Omega 3 for TG lowering David Colquhoun
15:00:00 Cases and Panel Discussion
15:30:00 Tea/ Coffee Break, Exhibition and Poster Viewing
16:00:00 Lipid Apheresis for elevated Lp(a)
16:00:00 Plenary 3 Ballroom Johan Strauss Apheresis
16:30:00 LDL Apheresis in 2014: What does the future hold
17:00:00 Concomittant Drug Therapy
20:00:00 Conference Dinner ( optional )
Sunday, December 7, 2014
08:00:00 FH Connect: Is it time for a global FH registry? Joep Banach Defesche
08:00:00 Plenary 4 Ballroom Johan S trauss FH and other genetic dyslipidemias (joint session with EAS and International FH Foundation) Olov Wiklund, Gerald F Watts
08:30:00 Models of Care Gerald F Watts
09:00:00 Challenges in FH
09:00:00 Challenges in FH
09:30:00 Workshop 6 Lipid Management In Diabetes And Chronic Kidney Disease Karam Kostner, Klaus G Parhofer
09:30:00 Workshop 5 Familial Dyslipidemias Joep Banach Defesche
09:30:00 Genetic Testing: Pros and Cons Joep Banach Defesche
09:30:00 Diabetic Dyslipidemia and its Therapy
10:00:00 Lipid Lowering Therapy in CKD Klaus G Parhofer
10:00:00 Treatment Options Ian Hamilton Craig
10:10:00 Association between Lipid Levels and Estimated Glomerular Filtration Rate in a Cohort of Patients with High Cardiovascular Risk
10:30:00 Cases and Panel Discussion
10:30:00 Cases and Panel Discussion
11:00:00 Tea/ Coffee Break, Exhibition and Poster Viewing
11:30:00 HDL Functionality
11:30:00 Plenary 5 Bal lroom Johan Strauss HDL,TG and Lp(a) Gerhard M. Kostner , Olov Wiklund
12:00:00 Treatment of triglycerides in cardiovascular prevention Olov Wiklund
12:30:00 Oral Abstracts David Colquhoun, Gerhard M. Kostner
12:30:00 Biomolecule Damage (DNA And Lipid) Is Elevated In Patients With Type 1 Diabetes With And Without Diabetic Complications
12:35:00 Persistenly Elevated Risk of Myocardial Infarction After Smoking Cessation. Do Lipids Play a Role?
12:40:00 Antihyperlipidemic effect of camel milk in experimental type 2 dia betic rats Govindasamy Chandramohan
12:45:00 Effect Of Lipids And Protein Intake On Progression Of Diabetic Renal Disease
12:50:00 A Comparison of Low and High dose Atorvastatin on Achieving Apolipoprotein B1 00, LDL - C and non - HDL - C Therapeutic Targets, HDL Functionality, Modified LDL and Cytokines in T2DM
12:55:00 Association between Pcsk9 and Metabolic Syndrome Markers in an Elderly Community of Sharpeville, SA
13:00:00 Comparative Study Between Sacha Inchi's Oil And Simvastatin: Effect On Lipemia Of Diabetic Patients Type 2 With Dislipoprotei nemia
13:05:00 Cardioprotective Effects Of Purified Histaminase From La thyrus Sativus Seedling In Myocardial Infarction Induced By Isoprenaline
13:15:00 Separation Of Postprandial Lipoproteins By Immuno - Affinity: A New Method Able To Evaluate The Effect Of Carbohydrate Diets On Postprandial Lipid Profile Jean E. Schwarzbauer
13:20:00 Plasma Ferritin Is Associated With Ins ulin Resistance Dyslipidemia in Healthy Men of Primary Prevention
13:25:00 Decreased Cardiovascular Events in Familial Hypercholesterolemic Patients Treated with Mipomersen, an Antisense Inhibitor of Apolipoprotein B Transl ation
14:00:00 Workshop 7 Diet and Nutraceuticals David Colquhoun
14:00:00 Workshop 8 Difficult To Treat Hyperlipidemia Maciej Banach
14:00:00 Evidence - based Nutraceuticals David Colquhoun
14:00:00 Case studies
14:30:00 Case studies
14:30:00 What is the B est Diet for Hyperlipidemia?
15:00:00 Lipoprotein Profiles Identified by Lipoprint System in Individual s with Dyslipoproteinemia
15:00:00 Cases and Panel Discussion
15:30:00 Tea/ Coffee Break, Exhibition and Poster Viewing
16:00:00 Plenary 6 Ballroom Johan Strauss Novel lipid lowering therapies, Focus on PCSK9 Gerald F Watts
16:00:00 PCSK9: Too good to be true? Maciej Banach
16:30:00 MTP and Antisense therapy
17:00:00 Other promising therapies Gerald F Watts
18:00:00 Closing Remarks Karam Kostner
3D Tissue Models
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.